Showing results (181-190 of 349) with videos related to
Sort By:
Pageof 35
The New England Journal of Medicine|February 9, 2007
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasisGerald G Krueger, Richard G Langley, Craig Leonardi, et al.The Cochrane Database of Systematic Reviews|February 27, 2013
Interventions for nail psoriasisAnna Christa Q de Vries, Nathalie A Bogaards, Lotty Hooft, et al.The Journal of Dermatological Treatment|December 11, 2023
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registryBruce Strober, Kristina Callis Duffin, Mark Lebwohl, et al.The New England Journal of Medicine|February 13, 2023
Phase 2 Trial of Difelikefalin in Notalgia ParestheticaBrian S Kim, Robert Bissonnette, Kristine Nograles, et al.Journal of the American Academy of Dermatology|April 21, 2004
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsMark Lebwohl, Scott Dinehart, David Whiting, et al.Archives of Dermatology|April 10, 2002
Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gelSusan Bershad, Giselle Kranjac Singer, Janice E Parente, et al.Journal of the American Academy of Dermatology|August 7, 2017
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b studyJerry Bagel, Kristina Callis Duffin, Angela Moore, et al.Journal of the American Academy of Dermatology|February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group reportWayne Carey, Scott Glazer, Alice B Gottlieb, et al.Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.Carcinogenesis|March 2, 2002
Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamageEileen Q Shyong, Yuhun Lu, Alison Lazinsky, et al.Pageof 35